explore -WSS

explore

author：leisure time 2025-10-02 22:57:56 - browse：19

The biotech company Acelyrin, which raised more than $500 million in an IPO this year, ran into its first major setback Monday as its investigational anti-inflammatory drug missed the primary goal in a pivotal clinical trial.

Acelyrin’s medicine, a subcutaneous treatment called izokibep, is meant to clear up lesions for patients with the common skin disease hidradenitis suppurativa, or HS, an inflammatory disorder that leads to abscesses and scars. But after 16 weeks of treatment, patients who received izokibep did not show significant improvements compared to those taking a placebo, failing the study’s primary endpoint.

Acelyrin’s share price fell more than 60% in after-hours trading Monday.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： As demand for Covid shots wanes, Moderna seeks its next success
Next article： What affirmative action's end means to a medical student

Wikipedia

WSS

Skip the lead apron during X

Top Ukrainian generals say counteroffensive is 'going to plan' as losses mount

Archived: an online chat discussing Ebola, vaccines, and a new epidemic

California store owner shot dead in dispute over displaying Pride flag: Police

Intellia plays down concerns on accidental germline transmission

What past blockbusters can tell us about future of Wegovy and other weight loss medicines

hotspot

explore

focus

Heart attack and stroke risk calculators need revising

Prescription digital therapeutics are key to pharma’s future

Medicare details structure of new drug price negotiation program

Security flaws in third

Wildfire smoke exposes gaps in outdoor worker protections

DeSantis wants to import drugs. Biden’s FDA blasted his plan

Bright Health sells Medicare Advantage business to Molina

Trump’s hydroxychloroquine hype: a risk to my treatment and to him

BioMarin wins approval for gene therapy to treat hemophilia A

Undocumented workers face uncertainty as immigration law takes effect in Florida

leisure time

PBMs are inflating the cost of generic drugs. They must be reined in

How the drug

Trans patients at the end of life deserve respect and dignity

Prescription digital therapeutics are key to pharma’s future

FDA greenlights medical device to combat bladder issues

Grandmother of French teen shot dead by police officer pleads with rioters to stop the violence

leisure time

Wikipedia

explore

entertainment